Popular
    Stacks and blends
    Muscle Building

    Overload stack (strongest)

    Hexarelin + CJC-1295 (no DAC)

    🎉 10% off all blends
    4.000.000 ₫

    3.600.000 ₫

    Vial-by-vial breakdown

    CJC-1295 no DAC (5mg)1.000.000 ₫
    2 × Hexarelin (5mg)1.500.000 ₫ each = 3.000.000 ₫
    Subtotal4.000.000 ₫
    Stack discount (10%)−400.000 ₫

    The maximum-output GH-axis stack. Hexarelin is the most potent GHRP characterised in published human work — producing a GH spike 2–3× larger than GHRP-6 and substantially larger than Ipamorelin at equivalent doses. CJC-1295 (no DAC) is paired specifically because its short ~30-min half-life keeps the GHRH signal pulsatile, preserving the synergistic spike rather than blunting it through tonic stimulation. The trade-off is real and disclosed: at sustained high doses Hexarelin produces a measurable rise in cortisol and prolactin, and the GHSR receptor desensitises after roughly 14–16 weeks of continuous use — which is why this stack is positioned for 8–12 week blocks rather than indefinite use. Dosed nightly. The combined effect has been shown to lift IGF-1 by ~78% in clinical work.

    Dosage

    Start CJC-1295 (no DAC) 50 mcg + Hexarelin 50 mcg once nightly; after 1 week double to 100 mcg of each nightly, in 8–12 week blocks (10mg / 5mg are vial sizes, not doses)

    Duration of effect

    Daily dosing; benefits build over weeks (plasma half-life: ~30-70 minutes)

    See full half-life table →

    Key Features

    • Maximum GH boost
    • Synergistic effects
    • Enhanced IGF-1
    • Muscle & recovery
    Contact Us

    Includes key details, half-life data, usage notes and research sources.

    Usage Instructions

    Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.

    Research Highlights

    • Backed by scientific research
    • Manufactured to pharmaceutical standards
    • Used in clinical research settings
    • Established safety profile

    Safety Information

    • •Consult your healthcare provider before use
    • •Not intended for pregnant or nursing women
    • •Store properly according to instructions
    • •Report any adverse effects to your healthcare provider

    Source: Journal of Clinical Endocrinology & Metabolism

    Clinical Research

    The CJC-1295 and Hexarelin combination increased IGF-1 levels by 78% and GH secretion by 5-10x, producing the most potent GH+IGF1 boost among peptide combinations.

    Read full study

    Additional Research

    Source: García-del-Barco-Herrera et al., Clin Med Insights Cardiol (2017)

    Comprehensive open-access review of the GHRP + GHRH-analogue combination strategy summarising the synergy that underpins all 'overload' protocols — including reproducible human GH/IGF-1 elevation and cardiac cytoprotection data.

    Read full study

    Human Clinical Trials

    • CJC-1295 in healthy adultsJournal of Clinical Endocrinology & Metabolism · 2006

      Two randomised placebo-controlled ascending-dose trials: sustained increases in growth hormone and IGF-1.

      Read the trial
    • Hexarelin dose-response studyEuropean Journal of Clinical Pharmacology · 1994

      Double-blind placebo-controlled rising-dose study in humans: dose-dependent growth hormone release.

      Read the trial
      12
      participants
    See the full trial library

    Related Products